Phathom Pharmaceuticals (PHAT) Asset Writedowns and Impairment (2024 - 2025)
Phathom Pharmaceuticals (PHAT) reported Asset Writedowns and Impairment of -$539000.0 for Q4 2025, down 549.17% year-over-year from $120000.0 in Q4 2024, and down 573.75% quarter-over-quarter from -$80000.0 in Q2 2025.
Phathom Pharmaceuticals (PHAT) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 2 years of Asset Writedowns and Impairment data on file, last reported at -$539000.0 in Q4 2025.
- Asset Writedowns and Impairment for Q4 2025 came in at -$539000.0, down 549.17% year-over-year; the trailing twelve-month figure through Mar 2026 was -$619000.0 (down 135.68% YoY), and the FY2025 annual result was $280000.0, down 66.51% from the prior year.
- Asset Writedowns and Impairment declined to -$539000.0 in Q4 2025 per PHAT's latest filing, from -$80000.0 in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $899000.0 in Q1 2025 and troughed at -$539000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Phathom Pharmaceuticals | 895.99 Mn | 712.23 Mn | 46.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -539,000.00 |
| Dec 31, 2025 | -539,000.00 |
| Jun 30, 2025 | -80,000.00 |
| Jun 30, 2025 | -80,000.00 |
| Mar 31, 2025 | 899,000.00 |
| Mar 31, 2025 | 899,000.00 |
| Dec 31, 2024 | 120,000.00 |
| Dec 31, 2024 | 120,000.00 |
| Sep 30, 2024 | 473,000.00 |
| Sep 30, 2024 | 473,000.00 |
| Jun 30, 2024 | 243,000.00 |
| Jun 30, 2024 | 243,000.00 |